Fusion Pharmaceuticals Inc. (FUSN) NASDAQ
$21.25 0.01 (0.05%)
Market Cap: $1.80B
As of 04/18/24 04:00 PM EDT. Market closed.
Fusion Pharmaceuticals Inc. (FUSN)
NASDAQ
$21.25
0.01 (0.05%)
Market Cap: $1.80B
As of 04/18/24 04:00 PM EDT. Market closed.
Add to Portfolio
fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of ... read more
fusion pharmaceuticals (www.fusionpharma.com) is a new pharmaceutical company located in hamilton, ontario, canada, that is focused on becoming the leader in the targeted alpha therapy field. fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. in addition to its lead program, fpx-01, fusion is building a pipeline of products through a protein discovery platform, that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. fusion’s technology development team also has proprietary methods for introducing alpha emitters into targeting molecules. read less
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
101
Address
.
PRICE CHART FOR FUSION PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$21.28
Previous Close
$21.24
Days Range
$21.20 - $21.30
52 week range
$2.31 - $21.55
Volume
329,205
Avg. Volume (30 days)
2,385,536
Market Cap
$1.80B
Dividend Yield
-
P/E
(18.99)
Shares Outstanding
84,865,021
Open
$21.28
Previous Close
$21.24
Days Range
$21.20 - $21.30
52 week range
$2.31 - $21.55
Volume
329,205
Avg. Volume (30 days)
2,385,536
Market Cap
$1.80B
Dividend Yield
-
P/E
(18.99)
Shares Outstanding
84,865,021
FINANCIAL STATEMENTS FOR FUSION PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR FUSION PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Khuong Chau Quang | Director | Nov 11, 2022 | Option Exercise | $2.38 | 42,093 | 100,181 | 42,093 | Nov 14, 2022, 08:31 AM |
| GANNON STEVEN | Director | Aug 11, 2022 | Buy | $2.03 | 44,400 | 90,132 | 56,400 | Aug 11, 2022, 04:19 PM |
| Valliant John | Chief Executive Officer | Apr 27, 2022 | Sale | $6.03 | 4,511 | 27,201 | 318,147 | Apr 27, 2022, 04:34 PM |
| Valliant John | Chief Executive Officer | Apr 26, 2022 | Sale | $6.07 | 2,147 | 13,032 | 322,658 | Apr 27, 2022, 04:34 PM |
| Valliant John | Chief Executive Officer | Apr 25, 2022 | Sale | $6.03 | 2,036 | 12,277 | 324,805 | Apr 27, 2022, 04:34 PM |
| Valliant John | Chief Executive Officer | Apr 21, 2022 | Sale | $6.01 | 922 | 5,541 | 326,841 | Apr 22, 2022, 08:04 PM |
| Valliant John | Chief Executive Officer | Apr 20, 2022 | Sale | $6.02 | 367 | 2,209 | 327,763 | Apr 22, 2022, 08:04 PM |
| Valliant John | Chief Executive Officer | Apr 12, 2022 | Sale | $7.10 | 18,255 | 129,610 | 340,124 | Apr 13, 2022, 06:10 PM |
| Valliant John | Chief Executive Officer | Apr 11, 2022 | Sale | $7.37 | 2,600 | 19,162 | 358,379 | Apr 13, 2022, 06:10 PM |
| Valliant John | Chief Executive Officer | Apr 13, 2022 | Sale | $6.41 | 11,994 | 76,882 | 328,130 | Apr 13, 2022, 06:10 PM |
| Valliant John | Chief Executive Officer | Apr 08, 2022 | Sale | $7.52 | 826 | 6,212 | 360,979 | Apr 08, 2022, 04:21 PM |
| Valliant John | Chief Executive Officer | Apr 07, 2022 | Sale | $7.56 | 1,255 | 9,488 | 361,805 | Apr 08, 2022, 04:21 PM |
| Valliant John | Chief Executive Officer | Apr 06, 2022 | Sale | $7.58 | 100 | 758 | 363,060 | Apr 08, 2022, 04:21 PM |
| Valliant John | Chief Executive Officer | Apr 04, 2022 | Sale | $7.81 | 700 | 5,467 | 365,260 | Apr 05, 2022, 05:01 PM |
| Valliant John | Chief Executive Officer | Apr 01, 2022 | Sale | $7.75 | 1,000 | 7,750 | 365,960 | Apr 05, 2022, 05:01 PM |
| Valliant John | Chief Executive Officer | Apr 05, 2022 | Sale | $7.67 | 2,100 | 16,107 | 363,160 | Apr 05, 2022, 05:01 PM |
| Valliant John | Chief Executive Officer | Mar 30, 2022 | Sale | $7.52 | 300 | 2,256 | 366,960 | Apr 01, 2022, 05:36 PM |
| Valliant John | Chief Executive Officer | Mar 29, 2022 | Sale | $7.52 | 200 | 1,504 | 367,260 | Mar 29, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 28, 2022 | Sale | $7.55 | 9,600 | 72,480 | 367,460 | Mar 29, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 25, 2022 | Sale | $7.42 | 500 | 3,710 | 377,060 | Mar 29, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 21, 2022 | Sale | $7.46 | 700 | 5,222 | 377,560 | Mar 24, 2022, 05:32 PM |
| Valliant John | Chief Executive Officer | Mar 23, 2022 | Sale | $7.50 | 100 | 750 | 378,260 | Mar 24, 2022, 05:32 PM |
| Valliant John | Chief Executive Officer | Mar 22, 2022 | Sale | $7.53 | 4,000 | 30,120 | 378,360 | Mar 24, 2022, 05:32 PM |
| Valliant John | Chief Executive Officer | Mar 21, 2022 | Sale | $7.47 | 1,500 | 11,205 | 382,360 | Mar 21, 2022, 05:47 PM |
| Valliant John | Chief Executive Officer | Mar 18, 2022 | Sale | $7.61 | 1,204 | 9,162 | 383,860 | Mar 21, 2022, 05:47 PM |
| Valliant John | Chief Executive Officer | Mar 17, 2022 | Sale | $7.51 | 900 | 6,759 | 385,064 | Mar 21, 2022, 05:47 PM |
| Valliant John | Chief Executive Officer | Mar 15, 2022 | Sale | $7.12 | 100 | 712 | 386,064 | Mar 16, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 14, 2022 | Sale | $6.96 | 1,300 | 9,048 | 386,164 | Mar 16, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 16, 2022 | Sale | $6.99 | 100 | 699 | 385,964 | Mar 16, 2022, 04:29 PM |
| Valliant John | Chief Executive Officer | Mar 11, 2022 | Sale | $7.13 | 100 | 713 | 387,464 | Mar 14, 2022, 04:18 PM |
| Valliant John | Chief Executive Officer | Mar 10, 2022 | Sale | $7.06 | 1,900 | 13,414 | 387,564 | Mar 14, 2022, 04:18 PM |
| Valliant John | Chief Executive Officer | Mar 09, 2022 | Sale | $6.94 | 822 | 5,705 | 389,464 | Mar 14, 2022, 04:18 PM |
| Valliant John | Chief Executive Officer | Mar 07, 2022 | Sale | $6.99 | 3,100 | 21,669 | 393,290 | Mar 08, 2022, 04:59 PM |
| Valliant John | Chief Executive Officer | Mar 04, 2022 | Sale | $7.32 | 8,400 | 61,488 | 396,390 | Mar 08, 2022, 04:59 PM |
| Valliant John | Chief Executive Officer | Mar 08, 2022 | Sale | $6.92 | 3,004 | 20,788 | 390,286 | Mar 08, 2022, 04:59 PM |
| Valliant John | Chief Executive Officer | Feb 28, 2022 | Sale | $7.40 | 3,100 | 22,940 | 432,383 | Feb 28, 2022, 07:13 PM |
| Valliant John | Chief Executive Officer | Feb 25, 2022 | Sale | $7.57 | 8,152 | 61,711 | 435,483 | Feb 28, 2022, 07:13 PM |
| Valliant John | Chief Executive Officer | Feb 24, 2022 | Sale | $7.41 | 2,500 | 18,525 | 443,635 | Feb 28, 2022, 07:13 PM |
| Valliant John | Chief Executive Officer | Feb 18, 2022 | Sale | $7.88 | 4,898 | 38,596 | 479,534 | Feb 23, 2022, 05:58 PM |
| Valliant John | Chief Executive Officer | Feb 23, 2022 | Sale | $7.77 | 29,299 | 227,653 | 446,135 | Feb 23, 2022, 05:58 PM |
| Valliant John | Chief Executive Officer | Feb 22, 2022 | Sale | $7.85 | 4,100 | 32,185 | 475,434 | Feb 23, 2022, 05:58 PM |
| Valliant John | Chief Executive Officer | Feb 17, 2022 | Sale | $7.98 | 1,700 | 13,566 | 484,432 | Feb 17, 2022, 05:39 PM |
| Valliant John | Chief Executive Officer | Feb 16, 2022 | Sale | $7.99 | 33,202 | 265,284 | 486,132 | Feb 17, 2022, 05:39 PM |
| Valliant John | Chief Executive Officer | Feb 15, 2022 | Sale | $8.33 | 12,600 | 104,958 | 519,334 | Feb 17, 2022, 05:39 PM |
| GANNON STEVEN | Director | Aug 23, 2021 | Buy | $7.99 | 2,829 | 22,590 | 12,000 | Aug 23, 2021, 06:28 PM |
| GANNON STEVEN | Director | Aug 18, 2021 | Buy | $8.05 | 171 | 1,377 | 6,171 | Aug 20, 2021, 04:10 PM |
| GANNON STEVEN | Director | Aug 19, 2021 | Buy | $8.05 | 3,000 | 24,150 | 9,171 | Aug 20, 2021, 04:10 PM |
| GANNON STEVEN | Director | Aug 16, 2021 | Buy | $8.10 | 6,000 | 48,600 | 6,000 | Aug 17, 2021, 04:05 PM |
| ADAMS STREET PARTNERS LLC | 10% Owner | Dec 24, 2020 | Sale | $12.32 | 3,800 | 46,816 | 1,457,115 | Dec 29, 2020, 04:01 PM |
| ADAMS STREET PARTNERS LLC | 10% Owner | Dec 23, 2020 | Sale | $12.39 | 4,569 | 56,610 | 1,458,699 | Dec 28, 2020, 04:02 PM |
| JOHNSON & JOHNSON | 10% Owner | Jun 30, 2020 | Buy | $17.00 | 725,000 | 12,325,000 | 3,670,516 | Jul 02, 2020, 04:58 PM |
| TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | Jun 30, 2020 | Buy | $17.00 | 250,000 | 4,250,000 | 2,551,794 | Jul 02, 2020, 04:34 PM |
| O'Leary James J | Chief Medical Officer | Jun 30, 2020 | Buy | $17.00 | 300 | 5,100 | 300 | Jul 02, 2020, 04:05 PM |
| Preston Heather | Director | Jun 30, 2020 | Buy | $17.00 | 8,823 | 149,991 | 8,823 | Jul 02, 2020, 04:05 PM |
| Crowley John J | Chief Financial Officer | Jun 30, 2020 | Buy | $17.00 | 6,500 | 110,500 | 6,500 | Jul 02, 2020, 04:04 PM |
| Khuong Chau Quang | Director | Jun 30, 2020 | Buy | $17.00 | 898,000 | 15,266,000 | 2,930,670 | Jul 02, 2020, 04:03 PM |
| Christenson Johan | Director | Jun 30, 2020 | Buy | $17.00 | 240,000 | 4,080,000 | 3,807,247 | Jul 02, 2020, 04:02 PM |
| HealthCap VII, L.P. | 10% Owner | Jun 30, 2020 | Buy | $17.00 | 240,000 | 4,080,000 | 3,807,247 | Jul 02, 2020, 04:02 PM |
| ORBIMED ADVISORS LLC | Director | Jun 30, 2020 | Buy | $17.00 | 705,900 | 12,000,300 | 2,930,670 | Jul 02, 2020, 04:02 PM |
| ORBIMED ADVISORS LLC | Director | Jun 30, 2020 | Buy | $17.00 | 192,100 | 3,265,700 | 192,100 | Jul 02, 2020, 04:02 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Khuong Chau Quang | Director | 11/11/2022 | 100,181 |
| GANNON STEVEN | Director | 08/11/2022 | 90,132 |
| Valliant John | Chief Executive Officer | 04/27/2022 | 27,201 |
| Valliant John | Chief Executive Officer | 04/26/2022 | 13,032 |
| Valliant John | Chief Executive Officer | 04/25/2022 | 12,277 |
| Valliant John | Chief Executive Officer | 04/21/2022 | 5,541 |
| Valliant John | Chief Executive Officer | 04/20/2022 | 2,209 |
| Valliant John | Chief Executive Officer | 04/12/2022 | 129,610 |
| Valliant John | Chief Executive Officer | 04/11/2022 | 19,162 |
| Valliant John | Chief Executive Officer | 04/13/2022 | 76,882 |
| Valliant John | Chief Executive Officer | 04/08/2022 | 6,212 |
| Valliant John | Chief Executive Officer | 04/07/2022 | 9,488 |
| Valliant John | Chief Executive Officer | 04/06/2022 | 758 |
| Valliant John | Chief Executive Officer | 04/04/2022 | 5,467 |
| Valliant John | Chief Executive Officer | 04/01/2022 | 7,750 |
| Valliant John | Chief Executive Officer | 04/05/2022 | 16,107 |
| Valliant John | Chief Executive Officer | 03/30/2022 | 2,256 |
| Valliant John | Chief Executive Officer | 03/29/2022 | 1,504 |
| Valliant John | Chief Executive Officer | 03/28/2022 | 72,480 |
| Valliant John | Chief Executive Officer | 03/25/2022 | 3,710 |
| Valliant John | Chief Executive Officer | 03/21/2022 | 5,222 |
| Valliant John | Chief Executive Officer | 03/23/2022 | 750 |
| Valliant John | Chief Executive Officer | 03/22/2022 | 30,120 |
| Valliant John | Chief Executive Officer | 03/21/2022 | 11,205 |
| Valliant John | Chief Executive Officer | 03/18/2022 | 9,162 |
| Valliant John | Chief Executive Officer | 03/17/2022 | 6,759 |
| Valliant John | Chief Executive Officer | 03/15/2022 | 712 |
| Valliant John | Chief Executive Officer | 03/14/2022 | 9,048 |
| Valliant John | Chief Executive Officer | 03/16/2022 | 699 |
| Valliant John | Chief Executive Officer | 03/11/2022 | 713 |
| Valliant John | Chief Executive Officer | 03/10/2022 | 13,414 |
| Valliant John | Chief Executive Officer | 03/09/2022 | 5,705 |
| Valliant John | Chief Executive Officer | 03/07/2022 | 21,669 |
| Valliant John | Chief Executive Officer | 03/04/2022 | 61,488 |
| Valliant John | Chief Executive Officer | 03/08/2022 | 20,788 |
| Valliant John | Chief Executive Officer | 02/28/2022 | 22,940 |
| Valliant John | Chief Executive Officer | 02/25/2022 | 61,711 |
| Valliant John | Chief Executive Officer | 02/24/2022 | 18,525 |
| Valliant John | Chief Executive Officer | 02/18/2022 | 38,596 |
| Valliant John | Chief Executive Officer | 02/23/2022 | 227,653 |
| Valliant John | Chief Executive Officer | 02/22/2022 | 32,185 |
| Valliant John | Chief Executive Officer | 02/17/2022 | 13,566 |
| Valliant John | Chief Executive Officer | 02/16/2022 | 265,284 |
| Valliant John | Chief Executive Officer | 02/15/2022 | 104,958 |
| GANNON STEVEN | Director | 08/23/2021 | 22,590 |
| GANNON STEVEN | Director | 08/18/2021 | 1,377 |
| GANNON STEVEN | Director | 08/19/2021 | 24,150 |
| GANNON STEVEN | Director | 08/16/2021 | 48,600 |
| ADAMS STREET PARTNERS LLC | 10% Owner | 12/24/2020 | 46,816 |
| ADAMS STREET PARTNERS LLC | 10% Owner | 12/23/2020 | 56,610 |
| JOHNSON & JOHNSON | 10% Owner | 06/30/2020 | 12,325,000 |
| TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | 06/30/2020 | 4,250,000 |
| O'Leary James J | Chief Medical Officer | 06/30/2020 | 5,100 |
| Preston Heather | Director | 06/30/2020 | 149,991 |
| Crowley John J | Chief Financial Officer | 06/30/2020 | 110,500 |
| Khuong Chau Quang | Director | 06/30/2020 | 15,266,000 |
| Christenson Johan | Director | 06/30/2020 | 4,080,000 |
| HealthCap VII, L.P. | 10% Owner | 06/30/2020 | 4,080,000 |
| ORBIMED ADVISORS LLC | Director | 06/30/2020 | 12,000,300 |
| ORBIMED ADVISORS LLC | Director | 06/30/2020 | 3,265,700 |
Load More Insider Transactions
FUNDS WITH A POSITION IN FUSION PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 6,401,000 | 1.14% | 126.74% | Other |
| ORBIMED ADVISORS LLC | 3,122,770 | 0.6% | No change | Other |
| BLACKROCK INC. | 419,806 | 0.0001% | 4986.71% | Other |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 400,000 | 0.00796% | New | Other |
| UBS OCONNOR LLC | 213,107 | 0.15% | -22.38% | Value |
| GEODE CAPITAL MANAGEMENT, LLC | 39,346 | 0.00004% | 27.47% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 10,000 | 0.00015% | New | Other |
CHANGE IN SHARES OUTSTANDING FOR FUSION PHARMACEUTICALS INC
STOCK BUYBACKS FOR FUSION PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
5.98%
1Q
06/30/2023
10.41%
2Q
03/31/2023
36.08%
3Q
09/30/2022
67.51%
5Q
06/30/2022
68.78%
6Q
03/31/2022
69.51%
7Q
12/31/2021
69.89%
8Q
09/30/2021
70.09%
9Q
06/30/2021
72.17%
10Q
03/31/2021
75.13%
11Q
09/30/2020
75.56%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR FUSION PHARMACEUTICALS INC
LOADING...